US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Serina Therapeutics, Inc.

5.63

-0.1153-2.01%

Post-market: 5.630.00000.00%19:55 EDT

Volume:3.05K

Turnover:17.40K

Market Cap:55.92M

PE:-3.72

High:5.95

Open:5.80

Low:5.29

Close:5.75

Loading ...

Overview Company News Filings

Serina Therapeutics Reports Q1 2025 Net Loss of $4.8M, EPS Improves to $(0.49) from $(5.38)

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Serina Therapeutics : May Offer and Sell Shares of Common Stock of up to $13.3 Mln From Time to Time

THOMSON REUTERS

Serina Therapeutics Inc: Files for Offering of 5,593,972 Shares of Common Stock

THOMSON REUTERS

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

BRIEF-Serina Therapeutics Secures $5 Million Funding

Serina Therapeutics Raises $5 Million for Clinical Development of Parkinson's Drug

MT Newswires Live

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of Ser-252 Into Clinical Development in Advanced Parkinson's Disease

THOMSON REUTERS

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

BRIEF-Serina Therapeutics Files For Mixed Shelf Of Upto $100 Million - SEC Filing

Serina Therapeutics files $100M mixed securities shelf

Serina Therapeutics: Files for Mixed Shelf of Upto $100 Mln - SEC Filing

THOMSON REUTERS

Serina Therapeutics FY24 EPS $(1.51) Down From $0.73 YoY, Total Revenues $56K Down From $3.15M YoY

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Seres Therapeutics Advances SER-155 Program with FDA Support

LPM progresses through Bynoe lithium development activities

The Market Herald

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

BRIEF-Serina Therapeutics Appoints Dr. Jay Venkatesan To Its Board Of Directors

Serina Therapeutics Appoints DR. Jay Venkatesan to Its Board of Directors

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SER/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SER","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SER\",,,,,undefined,":{"symbol":"SER","market":"US","secType":"STK","nameCN":"Serina Therapeutics, Inc.","latestPrice":5.63,"timestamp":1746820800000,"preClose":5.7453,"halted":0,"volume":3045,"hourTrading":{"tag":"盘后","latestPrice":5.63,"preClose":5.63,"latestTime":"19:55 EDT","volume":15,"amount":87.59,"timestamp":1746834955363},"delay":0,"floatShares":2757765,"shares":9932215,"eps":-1.513928,"marketStatus":"Market Closed","change":-0.1153,"latestTime":"05-09 16:00:00 EDT","open":5.8,"high":5.95,"low":5.2881,"amount":17402.516619,"amplitude":0.115207,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.513928,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"exchange":"AMEX","adjPreClose":5.7453,"preHourTrading":{"tag":"盘前","latestPrice":8.55,"preClose":5.7453,"latestTime":"09:28 EDT","volume":38,"amount":324.9,"timestamp":1746797285714},"postHourTrading":{"tag":"盘后","latestPrice":5.63,"preClose":5.63,"latestTime":"19:55 EDT","volume":15,"amount":87.59,"timestamp":1746834955363},"volumeRatio":1.674876984801066},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SER\",,,,,undefined,":{"symbol":"SER","floatShares":2757765,"roa":"-135.82%","roe":"-485.36%","lyrEps":-1.513928,"volumeRatio":1.674876984801066,"shares":9932215,"dividePrice":0,"high":5.95,"amplitude":0.115207,"preClose":5.7453,"low":5.2881,"week52Low":3.81,"pbRate":"32.87","psRate":"1096.44","week52High":14.57,"institutionHeld":0,"latestPrice":5.63,"eps":-1.513928,"divideRate":0,"volume":3045,"delay":0,"ttmEps":-1.513928,"open":5.8,"prevYearClose":5.01,"prevWeekClose":5.7873,"prevMonthClose":6.31,"prevQuarterClose":5.67,"fiveDayClose":5.7873,"twentyDayClose":4.8,"sixtyDayClose":4.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SER\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2534641031","title":"Serina Therapeutics Reports Q1 2025 Net Loss of $4.8M, EPS Improves to $(0.49) from $(5.38)","url":"https://stock-news.laohu8.com/highlight/detail?id=2534641031","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534641031?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:16","pubTimestamp":1746735387,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nNDLbXhR9K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER"],"gpt_icon":0},{"id":"2531920241","title":"Serina Therapeutics to Present at JonesResearch Virtual CNS Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2531920241","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531920241?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:00","pubTimestamp":1745920800,"startTime":"0","endTime":"0","summary":"HUNTSVILLE, AL, April 29, 2025  -- Serina Therapeutics, Inc.  , a clinical-stage biotechnology company developing its proprietary POZ Platformdrug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the JonesResearch Hosts: Virtual CNS Day on April 29, 2025, at 12:00 p.m. EDT.Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTMprovides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates . Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/serina-therapeutics-present-jonesresearch-virtual-100000150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","BK4007","BK4139","LENZ","SER","CNS"],"gpt_icon":0},{"id":"2530473562","title":"Serina Therapeutics :  May Offer and Sell Shares of Common Stock of up to $13.3 Mln From Time to Time","url":"https://stock-news.laohu8.com/highlight/detail?id=2530473562","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530473562?lang=en_us&edition=fundamental","pubTime":"2025-04-28 18:15","pubTimestamp":1745835340,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nFWN3R61MQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2528560054","title":"Serina Therapeutics Inc:  Files for Offering of 5,593,972 Shares of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2528560054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528560054?lang=en_us&edition=fundamental","pubTime":"2025-04-18 18:08","pubTimestamp":1744970906,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250418:nFWN3QV2ZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2527495082","title":"Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2527495082","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527495082?lang=en_us&edition=fundamental","pubTime":"2025-04-15 18:30","pubTimestamp":1744713000,"startTime":"0","endTime":"0","summary":"HUNTSVILLE, AL, April 15, 2025  -- Serina Therapeutics, Inc. , a clinical-stage biotechnology company developing its proprietary POZ Platformdrug optimization technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development Officer, will present new data at the 4th LNP Formulation & Process Development Summit 2025 in Boston, MA. The presentation, titled \"The PEG Dilemma – A Solution,\" will take place on Tuesday, April 15, at 9:30 AM ET. The session will focus on addressing challenges related to anti-PEG antibodies in mRNA vaccines and therapeutics and introduces Serina's POZ-lipid technology as an immune-silent alternative to PEG-lipids.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/serina-therapeutics-present-4th-lnp-103000552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SMMF","BK4585","IE00BMG7P694.USD","BK4211","IE00BMG7P819.SGD","IE00BMG7P926.USD","IE00BD4GTW91.USD","IE00BD4GTV84.USD","BK4208","BK4588","IE00BD4GTT62.SGD","PEG","IE00BMG7P587.USD","LENZ","BK4007","BK4139","SER"],"gpt_icon":0},{"id":"2526826046","title":"BRIEF-Serina Therapeutics Secures $5 Million Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2526826046","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526826046?lang=en_us&edition=fundamental","pubTime":"2025-04-09 05:56","pubTimestamp":1744149412,"startTime":"0","endTime":"0","summary":"BRIEF-Serina Therapeutics Secures $5 Million FundingApril 8 (Reuters) - Serina Therapeutics Inc SER.A:SERINA THERAPEUTICS SECURES $5 MILLION IN FUNDING TO SUPPORT ADVANCEMENT OF SER-252 INTO CLINICAL ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1J0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2526823927","title":"Serina Therapeutics Raises $5 Million for Clinical Development of Parkinson's Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2526823927","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526823927?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:45","pubTimestamp":1744145131,"startTime":"0","endTime":"0","summary":"Serina Therapeutics  said Tuesday that it raised $5 million in financing from shareholders, which will be utilized to support the development of POZ-apomorphine to treat Advanced Parkinson's disease.The phase 1 clinical trial of the candidate is expected to commence in Q4, the company said.The company raised the financing by issuing 965,250 shares of convertible preferred stock at $5.18 per share.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","SER","BK7095","BK4139","BK4007","SER.AU"],"gpt_icon":0},{"id":"2526828103","title":"Serina Therapeutics Secures $5 Million in Funding to Support Advancement of Ser-252 Into Clinical Development in Advanced Parkinson's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2526828103","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526828103?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:30","pubTimestamp":1744144209,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1J0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2526287338","title":"Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2526287338","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526287338?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:30","pubTimestamp":1744144200,"startTime":"0","endTime":"0","summary":"HUNTSVILLE, Ala., April  08, 2025  (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform drug op","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3058022/0/en/Serina-Therapeutics-Secures-5-Million-in-Funding-to-Support-Advancement-of-SER-252-into-Clinical-Development-in-Advanced-Parkinson-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK4139","IE0031619046.USD","AEIS","SER","BK4157"],"gpt_icon":0},{"id":"2524446116","title":"BRIEF-Serina Therapeutics Files For Mixed Shelf Of Upto $100 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2524446116","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524446116?lang=en_us&edition=fundamental","pubTime":"2025-04-03 04:29","pubTimestamp":1743625774,"startTime":"0","endTime":"0","summary":"BRIEF-Serina Therapeutics Files For Mixed Shelf Of Upto $100 Million - SEC FilingApril 2  - Serina Therapeutics Inc SER.A:SERINA THERAPEUTICS: FILES FOR MIXED SHELF OF UPTO $100 MILLION - SEC FILINGSource text: [ID:n0001628280-25-016189]Further company coverage: SER.A ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG16J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2524446576","title":"Serina Therapeutics files $100M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2524446576","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524446576?lang=en_us&edition=fundamental","pubTime":"2025-04-03 04:20","pubTimestamp":1743625223,"startTime":"0","endTime":"0","summary":"16:18 EDT Serina Therapeutics (SER) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/serina-therapeutics-files-100m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/serina-therapeutics-files-100m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SER","BK4139","LENZ"],"gpt_icon":0},{"id":"2524452324","title":"Serina Therapeutics: Files for Mixed Shelf of Upto $100 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2524452324","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524452324?lang=en_us&edition=fundamental","pubTime":"2025-04-03 04:17","pubTimestamp":1743625047,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG16J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2522294700","title":"Serina Therapeutics FY24 EPS $(1.51) Down From $0.73 YoY, Total Revenues $56K Down From $3.15M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2522294700","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522294700?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:38","pubTimestamp":1742848723,"startTime":"0","endTime":"0","summary":"Serina Therapeutics FY24 EPS $(1.51) Down From $0.73 YoY, Total Revenues $56K Down From $3.15M YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44465603/serina-therapeutics-fy24-eps-1-51-down-from-0-73-yoy-total-revenues-56k-down-from-3-15m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSS","SER","LENZ"],"gpt_icon":0},{"id":"2522861085","title":"Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522861085","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522861085?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:30","pubTimestamp":1742848200,"startTime":"0","endTime":"0","summary":"HUNTSVILLE, March 24, 2025  -- Serina Therapeutics, Inc.  , a clinical-stage biotechnology company developing its proprietary POZ Platform drug optimization technology, today reported its financial results for the full year ended December31, 2024 and provided recent business highlights.\"We are encouraged by the progress we’ve made this year. Our partnership with Enable Injections’ wearable technology, combined with our POZ optimization technology, is poised to deliver a differentiated product profile and potential best-in-class therapy for advanced Parkinson’s patient care. We are on track towards our goal of dosing the first patient in a Phase 1b clinical trial in the fourth quarter,” said Steve Ledger, CEO of Serina Therapeutics. \"We also continue to advance our POZ Platform in addressing complex neurological needs and remain committed to pushing the boundaries of the platform’s potential in RNA and ADC therapeutics innovation to improve patient outcomes and quality of life.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/serina-therapeutics-reports-full-2024-203000895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4205","BK4528","BK4233","UK","LENZ","BK4139","SER"],"gpt_icon":0},{"id":"2521741975","title":"Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2521741975","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521741975?lang=en_us&edition=fundamental","pubTime":"2025-03-24 18:30","pubTimestamp":1742812200,"startTime":"0","endTime":"0","summary":"HUNTSVILLE, AL, March 24, 2025  -- Serina Therapeutics, Inc.  , a clinical-stage biotechnology company developing its proprietary POZ Platformdrug delivery technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development Officer, will present new data at the ACS Spring 2025 Meeting and Expo in San Diego, CA. His presentation, titled \"A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly Lipid Nanoparticles,\" will highlight findings on the immunogenic profile of Serina’s proprietary POZ-lipid technology.Dr. Moreadith will share data demonstrating that Serina’s POZ-lipid, a key component of lipid nanoparticles , did not trigger an IgM or IgG antibody response following repeat dosing in rats. In contrast, polyethylene glycol -lipid standards, commonly used in current LNP formulations, elicited a strong and boosted antibody response.Anti-PEG antibodies have been implicated as a potential cause of anaphylaxis and other serious adverse events observed in humans receiv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/serina-therapeutics-present-american-chemistry-103000665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","IE00BMG7P819.SGD","BK4117","BK4585","BK4208","IE00BMG7P926.USD","IE00BD4GTV84.USD","LENZ","IE00BMG7P694.USD","IE00BMG7P587.USD","BK4107","SER","PEG","IE00BD4GTW91.USD","IE00BD4GTT62.SGD","BK4588","BK4139"],"gpt_icon":0},{"id":"2519812223","title":"Seres Therapeutics Advances SER-155 Program with FDA Support","url":"https://stock-news.laohu8.com/highlight/detail?id=2519812223","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519812223?lang=en_us&edition=fundamental","pubTime":"2025-03-14 11:57","pubTimestamp":1741924660,"startTime":"0","endTime":"0","summary":"Seres Therapeutics Inc. ( ($MCRB) ) has released its Q4 earnings. Here is a breakdown of the information Seres Therapeutics Inc. presented to its i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/seres-therapeutics-advances-ser-155-program-with-fda-support?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/seres-therapeutics-advances-ser-155-program-with-fda-support?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SER","MCRB"],"gpt_icon":0},{"id":"2518763608","title":"LPM progresses through Bynoe lithium development activities","url":"https://stock-news.laohu8.com/highlight/detail?id=2518763608","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518763608?lang=en_us&edition=fundamental","pubTime":"2025-03-11 13:57","pubTimestamp":1741672620,"startTime":"0","endTime":"0","summary":"Lithium Plus Minerals Ltd  has ticked off a suite of development activities at its 4.09 million-tonne Bynoe Lithium Project in the Northern Territory, including metallurgical testing, planning for its mine and crucial infrastructure, and discussions about offtake.The project – located close to Darwin – is built around the Lei deposit, which carries a mineral resource estimate  of 4.09 million tonnes at 1.43% Li2O , numbers which LPM believes put it among the top deposits for this commodity in Australia.Development activity also sought to boost and define the quality of the resource. This included a 51% uplift in head-grade  at 57.8% mass yield for 87% lithia recovery – achieved through ore sorting trails – which allowed for the reduction of about 42% of low-grade material into a waste stream.LPM has also conducted metallurgical test work on the ore, achieving 85.3% recovery to a concentrate of 6.12% Li2O from DMS and fines and middlings flotation on a high-grade sample.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/lpm-progresses-through-bynoe-lithium-development-activities-2025-03-11/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7509","BK7504","BK7145","PLS.AU","TIA.AU","BK4139","MRE.AU","SER.AU","BK7095","LPM.AU","SER","BK7507"],"gpt_icon":0},{"id":"2516687257","title":"Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach","url":"https://stock-news.laohu8.com/highlight/detail?id=2516687257","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516687257?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:00","pubTimestamp":1741003200,"startTime":"0","endTime":"0","summary":"FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy endpoint of reduction in bloodstream infections  as of 30 days post HSCT in the next study. Seres has submitted clarification questions to FDA and expects a response in the coming weeks, which will inform the proposed protocol for the next SER-155 study in allo-HSCT, which the Company anticipates submitting to FDA in Q2. About SER-155SER-155 is an investigational, oral, live biotherapeutic designed to decolonize GI pathogens, improve epithelial barrier integrity, and induce immune tolerance to prevent bacterial bloodstream and antimicrobial resistant  infections, as well as other patho","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/seres-therapeutics-receives-feedback-fda-120000783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","HSCT","MCRB","SER","AMR","BK4139","BK4006","BK4585"],"gpt_icon":0},{"id":"2511046539","title":"BRIEF-Serina Therapeutics Appoints Dr. Jay Venkatesan To Its Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2511046539","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511046539?lang=en_us&edition=fundamental","pubTime":"2025-02-13 06:49","pubTimestamp":1739400588,"startTime":"0","endTime":"0","summary":"BRIEF-Serina Therapeutics Appoints Dr. Jay Venkatesan To Its Board Of DirectorsSerina Therapeutics Inc SER.A:SERINA THERAPEUTICS APPOINTS DR. JAY VENKATESAN TO ITS BOARD OF DIRECTORSSource text: ID:nGNX9m5B6xFurther company coverage: SER.A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nTUA4SQB2D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2511681580","title":"Serina Therapeutics Appoints DR. Jay Venkatesan to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2511681580","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511681580?lang=en_us&edition=fundamental","pubTime":"2025-02-13 05:15","pubTimestamp":1739394900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nTUA4SQB2D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SER","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":48,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SER\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-24","symbol":"SER","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2024-11-12","symbol":"SER","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":0.13},{"market":"US","date":"2024-08-09","symbol":"SER","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"post","actualEps":0.51},{"market":"US","date":"2024-05-14","symbol":"SER","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":-3.38},{"market":"US","date":"2024-03-22","symbol":"SER","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711080000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SER\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SER\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1741665600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SER\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SER","date":"2025-05-09","current":-5.121942,"percent":0.753846,"low":-19.318735,"twenty":-9.696231,"median":-6.287604,"eighty":-4.698211,"high":37.356482,"avg":-4.047784,"sd":9.903313,"marketCap":57063554},"quantilePoints":[{"date":"2024-04-05","current":29.141387,"twenty":30.584579,"median":32.083279,"eighty":33.732959,"marketCap":105541506},{"date":"2024-04-12","current":17.770243,"twenty":17.783016,"median":23.543628,"eighty":32.232039,"marketCap":93646584},{"date":"2024-04-19","current":17.456349,"twenty":17.731924,"median":17.945869,"eighty":31.172957,"marketCap":91992413},{"date":"2024-04-26","current":14.673941,"twenty":16.787882,"median":17.778226,"eighty":29.502185,"marketCap":77329529},{"date":"2024-05-03","current":14.209648,"twenty":14.673941,"median":17.57865,"eighty":21.283439,"marketCap":74882770},{"date":"2024-05-10","current":14.050147,"twenty":14.209648,"median":17.078432,"eighty":18.800885,"marketCap":74042223},{"date":"2024-05-17","current":12.820759,"twenty":14.187327,"median":15.966076,"eighty":18.090969,"marketCap":67563528},{"date":"2024-05-24","current":15.167772,"twenty":14.187327,"median":15.718602,"eighty":17.818141,"marketCap":79931945},{"date":"2024-05-31","current":-13.721878,"twenty":13.545619,"median":15.079879,"eighty":17.786209,"marketCap":79931945},{"date":"2024-06-07","current":-14.08298,"twenty":12.926135,"median":14.744671,"eighty":17.776629,"marketCap":82035417},{"date":"2024-06-14","current":-14.564515,"twenty":-13.557216,"median":14.673941,"eighty":17.770243,"marketCap":84840426},{"date":"2024-06-21","current":-15.922863,"twenty":-13.825876,"median":14.209648,"eighty":17.731924,"marketCap":92753004},{"date":"2024-06-28","current":-12.919404,"twenty":-13.944317,"median":14.209648,"eighty":17.655287,"marketCap":75257414},{"date":"2024-07-05","current":-11.364849,"twenty":-13.990538,"median":14.209648,"eighty":17.52973,"marketCap":66201907},{"date":"2024-07-12","current":-11.153551,"twenty":-13.799876,"median":13.810656,"eighty":17.339222,"marketCap":64971062},{"date":"2024-07-15","current":-13.477836,"twenty":-13.773877,"median":13.571165,"eighty":17.280659,"marketCap":78510363},{"date":"2024-08-02","current":-12.964682,"twenty":-13.747877,"median":13.539233,"eighty":17.222095,"marketCap":75521166},{"date":"2024-08-09","current":-11.364095,"twenty":-13.723872,"median":13.251843,"eighty":17.027373,"marketCap":66197511},{"date":"2024-08-16","current":-8.441425,"twenty":-13.721878,"median":2.384851,"eighty":16.171527,"marketCap":59150297},{"date":"2024-08-23","current":-10.330099,"twenty":-13.617881,"median":-8.582039,"eighty":15.966076,"marketCap":72384510},{"date":"2024-08-30","current":-10.13985,"twenty":-13.52255,"median":-9.00413,"eighty":15.966076,"marketCap":71051408},{"date":"2024-09-06","current":-10.104487,"twenty":-13.488788,"median":-9.975078,"eighty":15.85112,"marketCap":70803616},{"date":"2024-09-13","current":-7.831133,"twenty":-13.268937,"median":-9.379361,"eighty":15.707426,"marketCap":54873890},{"date":"2024-09-20","current":-7.554188,"twenty":-13.112179,"median":-8.839249,"eighty":15.365752,"marketCap":52933298},{"date":"2024-09-27","current":-9.43006,"twenty":-13.019016,"median":-9.049816,"eighty":15.0623,"marketCap":66077809},{"date":"2024-10-04","current":-8.251303,"twenty":-12.937515,"median":-8.845695,"eighty":14.905865,"marketCap":57818083},{"date":"2024-10-11","current":-8.580848,"twenty":-12.554189,"median":-8.732946,"eighty":14.786183,"marketCap":60127254},{"date":"2024-10-18","current":-9.769745,"twenty":-12.214089,"median":-8.764633,"eighty":14.702233,"marketCap":68458031},{"date":"2024-10-25","current":-8.872369,"twenty":-11.941393,"median":-8.872369,"eighty":14.673941,"marketCap":62169982},{"date":"2024-10-31","current":-8.568173,"twenty":-11.747964,"median":-8.847019,"eighty":14.628789,"marketCap":60038439},{"date":"2024-11-08","current":-5.742165,"twenty":-11.5456,"median":-8.764633,"eighty":14.420496,"marketCap":40236191},{"date":"2024-11-15","current":-6.048407,"twenty":-11.364849,"median":-8.720054,"eighty":14.209648,"marketCap":44459880},{"date":"2024-11-22","current":-5.928673,"twenty":-11.364547,"median":-8.695365,"eighty":14.209648,"marketCap":43570682},{"date":"2024-11-29","current":-6.352149,"twenty":-11.321986,"median":-8.600455,"eighty":14.209648,"marketCap":46682874},{"date":"2024-12-06","current":-7.456945,"twenty":-11.110513,"median":-8.568173,"eighty":14.187327,"marketCap":54802179},{"date":"2024-12-13","current":-6.006451,"twenty":-10.914992,"median":-8.561836,"eighty":14.088465,"marketCap":44142287},{"date":"2024-12-20","current":-7.07266,"twenty":-10.789111,"median":-8.479449,"eighty":13.954351,"marketCap":51978012},{"date":"2024-12-27","current":-6.747673,"twenty":-10.659517,"median":-8.390726,"eighty":13.571165,"marketCap":49589633},{"date":"2025-01-03","current":-6.517639,"twenty":-10.562175,"median":-8.162579,"eighty":13.520073,"marketCap":47899077},{"date":"2025-01-10","current":-5.904214,"twenty":-10.499761,"median":-8.051056,"eighty":13.363605,"marketCap":43390929},{"date":"2025-01-17","current":-6.07035,"twenty":-10.463782,"median":-7.83254,"eighty":13.258229,"marketCap":44611886},{"date":"2025-01-24","current":-6.006451,"twenty":-10.451708,"median":-7.712623,"eighty":13.14966,"marketCap":44142287},{"date":"2025-01-31","current":-5.878654,"twenty":-10.421318,"median":-7.617562,"eighty":12.926135,"marketCap":43203089},{"date":"2025-02-07","current":-5.878654,"twenty":-10.364245,"median":-7.402632,"eighty":5.571028,"marketCap":43203089},{"date":"2025-02-14","current":-5.955332,"twenty":-10.299629,"median":-7.207741,"eighty":-5.38422,"marketCap":43766608},{"date":"2025-02-21","current":-6.249265,"twenty":-10.231108,"median":-7.041606,"eighty":-5.510713,"marketCap":45926762},{"date":"2025-02-28","current":-6.380056,"twenty":-10.13985,"median":-6.713492,"eighty":-5.574659,"marketCap":46887966},{"date":"2025-03-07","current":-6.326216,"twenty":-10.13478,"median":-6.696682,"eighty":-5.743169,"marketCap":46492287},{"date":"2025-03-14","current":-5.532074,"twenty":-10.112497,"median":-6.684888,"eighty":-5.743169,"marketCap":40656021},{"date":"2025-03-21","current":-6.110856,"twenty":-10.104487,"median":-6.616553,"eighty":-5.743169,"marketCap":44909571},{"date":"2025-03-28","current":-4.234631,"twenty":-10.098885,"median":-6.511249,"eighty":-5.532216,"marketCap":47178021},{"date":"2025-04-04","current":-4.894342,"twenty":-10.073941,"median":-6.460817,"eighty":-4.926436,"marketCap":54527860},{"date":"2025-04-11","current":-4.279206,"twenty":-10.051126,"median":-6.404799,"eighty":-4.716041,"marketCap":47674632},{"date":"2025-04-17","current":-4.680381,"twenty":-10.000427,"median":-6.391338,"eighty":-4.680381,"marketCap":52144128},{"date":"2025-04-25","current":-5.429242,"twenty":-9.949728,"median":-6.352149,"eighty":-4.680381,"marketCap":60487189},{"date":"2025-05-02","current":-4.733871,"twenty":-9.769745,"median":-6.319486,"eighty":-4.680381,"marketCap":52740061},{"date":"2025-05-09","current":-5.121942,"twenty":-9.696231,"median":-6.287604,"eighty":-4.698211,"marketCap":57063554}],"updateTime":1746997845532}}}